Comparative analysis of three methods in anti-dsDNA antibodies detection: implications for Systemic Lupus Erythematosus diagnosis.
Autoantibodies
Immunoblotting
SLE
dsDNA
Journal
Scandinavian journal of immunology
ISSN: 1365-3083
Titre abrégé: Scand J Immunol
Pays: England
ID NLM: 0323767
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
revised:
07
11
2021
received:
01
06
2021
accepted:
01
12
2021
pubmed:
6
12
2021
medline:
27
1
2022
entrez:
5
12
2021
Statut:
ppublish
Résumé
The evaluation of anti-dsDNA antibodies represents one of the essential diagnostic and prognostic marker features in patients affected by Systemic Lupus Erythematosus (SLE). In this study, we have compared immunoblotting (IB) with Crithidia luciliae indirect immunofluorescence test (CLIFT) and chemiluminescent immunoassay (CLIA) in 91 patients referred to our hospital for anti-dsDNA antibodies detection. The concordance and correlation measured by Cohen's kappa and Spearman's coefficient respectively was significant between CLIFT and CLIA (0.70; 0,7404, P < .0001) and among CLIA and IB (0.79; 0,5377, P < 0,0001) and lower between CLIFT and IB (0.55; 0,4373, P <0,0001). Among the 46 IB-positive samples, 14 were positive for either CLIA or CLIFT. It is noteworthy that 11 out of these 14 samples had the final diagnosis of SLE. Thirteen out of fourteen samples were also positive for anti-nucleosome antibodies as measured concomitantly in immunoblotting. While our observations are based on a limited number of samples and will have to be confirmed in a bigger cohort, they underline the contribution of immunoblotting as an additional assay in defining the anti-dsDNA antibody profile in association with other well-established methods such as CLIA and CLIFT.
Substances chimiques
Antibodies, Antinuclear
0
anti-dsDNA autoantibody
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13123Subventions
Organisme : Lega Italiana per la lotta contro tumori (LILT)
Informations de copyright
© 2021 The Scandinavian Foundation for Immunology.
Références
Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis & Rheumatology (Hoboken, NJ). 2019;71:1400-1412.
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677-2686.
Andrejevic S, Jeremic I, Sefik-Bukilica M, et al. Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity. Clin Rheumatol. 2013;32:1619-1626.
Arbuckle MR, James JA, Kohlhase KF, et al. Development of anti-dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus. Scand J Immunol. 2001;54(1-2):211-219. 10.1046/j.1365-3083.2001.00959.x
Compagno M, Jacobsen S, Rekvig OP, et al. Low diagnostic and predictive value of anti-dsDNA antibodies in unselected patients with recent onset of rheumatic symptoms: results from a long-term follow-up Scandinavian multicentre study. Scand J Rheumatol. 2013;42(4):311-316. 10.3109/03009742.2013.765032
Agmon-Levin N, Damoiseaux J, Kallenberg C, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014;73:17-23.
McHugh ML. Interrater reliability: the kappa statistic. Biochemia Medica. 2012;22:276-282. 10.11613/BM.2012.031
Infantino M, Manfredi M, Merone M, et al. Analytical variability in the determination of anti-double-stranded DNA antibodies: the strong need of a better definition of the old and new tests. Immunol Res. 2018;66(3):340-347. 10.1007/s12026-018-8992-9
Locker JD, Medof ME, Bennett RM, et al. Characterization of DNA used to assay sera for anti-DNA antibodies; determination of the specificities of anti-DNA antibodies in SLE and non-SLE rheumatic disease states. J immunol (Baltimore, Md : 1950). 1977;118:694-701.
Kurien BT, Scofield RH. Autoantibody determination in the diagnosis of systemic lupus erythematosus. Scand J Immunol. 2006;64(3):227-235. 10.1111/j.1365-3083.2006.01819.x
Mummert E, Fritzler MJ, Sjöwall C, et al. The clinical utility of anti-double-stranded DNA antibodies and the challenges of their determination. J Immunol Methods. 2018;459:11-19. 10.1016/j.jim.2018.05.014
Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288-291.
Hillebrand JJ, Bernelot Moens HJ, Mulder AH. Changes in Farr radioimmunoassay and EliA fluorescence immunoassay anti-dsDNA in relation to exacerbation of SLE. Lupus. 2013;22(11):1169-1173. 10.1177/096120331350036.
Shovman O, Gilburd B, Barzilai O, et al. Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. Ann N Y Acad Sci. 2005;1050(1):380-388. 10.1196/annals.1313.120
Infantino M, Meacci F, Bentow C, et al. Clinical comparison of QUANTA Flash dsDNA chemiluminescent immunoassay with four current assays for the detection of anti-dsDNA autoantibodies. J Immunol Res. 2015;2015:1-8 902821.
Bentow C, Lakos G, Martis P, et al. International multi-center evaluation of a novel chemiluminescence assay for the detection of anti-dsDNA antibodies. Lupus. 2016;25(8):864-872. 10.1177/0961203316640917
Enocsson H, Sjöwall C, Wirestam L, et al. Four Anti-dsDNA Antibody Assays in Relation to Systemic Lupus Erythematosus Disease Specificity and Activity. J Rheumatol. 2015;42(5):817-825. 10.3899/jrheum.140677
de Leeuw K, Bungener L, Roozendaal C, et al. Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: comparison of different assays during quiescent and active disease. Rheumatology (Oxford, England). 2017;1(56):698-703.
van der Vlag J, Berden JH. Lupus nephritis: role of antinucleosome autoantibodies. Semin Nephrol. 2011;31(4):376-389. 10.1016/j.semnephrol.2011.06.009